KR101207214B1 - A composition for the prevention and treatment of inflammatory disease comprising the fractions of Glehnia littoralis as an active ingredient - Google Patents
A composition for the prevention and treatment of inflammatory disease comprising the fractions of Glehnia littoralis as an active ingredient Download PDFInfo
- Publication number
- KR101207214B1 KR101207214B1 KR1020100003903A KR20100003903A KR101207214B1 KR 101207214 B1 KR101207214 B1 KR 101207214B1 KR 1020100003903 A KR1020100003903 A KR 1020100003903A KR 20100003903 A KR20100003903 A KR 20100003903A KR 101207214 B1 KR101207214 B1 KR 101207214B1
- Authority
- KR
- South Korea
- Prior art keywords
- methanol
- fraction
- extract
- prevention
- inflammatory diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 51
- 230000002265 prevention Effects 0.000 title claims abstract description 30
- 239000004480 active ingredient Substances 0.000 title claims abstract description 27
- 244000146486 Glehnia littoralis Species 0.000 title claims abstract description 10
- 235000004036 Glehnia littoralis Nutrition 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 101
- 238000004519 manufacturing process Methods 0.000 claims abstract description 32
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 30
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 30
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 19
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims abstract description 13
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract description 13
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 201
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 81
- 239000002032 methanolic fraction Substances 0.000 claims description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 31
- 239000002537 cosmetic Substances 0.000 claims description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 24
- 230000006872 improvement Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000003674 animal food additive Substances 0.000 claims description 15
- 238000005194 fractionation Methods 0.000 claims description 12
- 208000001640 Fibromyalgia Diseases 0.000 claims description 10
- 206010034464 Periarthritis Diseases 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 7
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 7
- 208000030090 Acute Disease Diseases 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 201000002481 Myositis Diseases 0.000 claims description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 6
- 206010033078 Otitis media Diseases 0.000 claims description 6
- 201000007100 Pharyngitis Diseases 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 6
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
- 208000000491 Tendinopathy Diseases 0.000 claims description 6
- 206010043255 Tendonitis Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 201000003146 cystitis Diseases 0.000 claims description 6
- 201000005917 gastric ulcer Diseases 0.000 claims description 6
- 208000014617 hemorrhoid Diseases 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000008383 nephritis Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 201000001245 periodontitis Diseases 0.000 claims description 6
- 201000003068 rheumatic fever Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 206010039083 rhinitis Diseases 0.000 claims description 6
- 230000009897 systematic effect Effects 0.000 claims description 6
- 201000004415 tendinitis Diseases 0.000 claims description 6
- 206010044008 tonsillitis Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 4
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 abstract description 15
- 230000002757 inflammatory effect Effects 0.000 abstract description 14
- 230000003013 cytotoxicity Effects 0.000 abstract description 10
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 10
- 230000028327 secretion Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 4
- 210000000172 cytosol Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 238000002360 preparation method Methods 0.000 description 26
- 239000002044 hexane fraction Substances 0.000 description 19
- 239000002038 ethyl acetate fraction Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 239000002034 butanolic fraction Substances 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 239000012223 aqueous fraction Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 9
- -1 patch Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000009161 herbalism Methods 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 해방풍(Glehnia littoralis) 추출물로부터 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물에 관한 것으로서, 더욱 상세하게는, 해방풍 추출물을 유기용매로 분획하여 제조한 분획물은 염증성 사이토카인인 인터루킨-1β(interleukin-1β, IL-1β) 및 종양괴사인자-α(tumor necrosis factor-α, TNF-α)의 생산 또는 분비를 억제하고, 세포독성이 없는 안전한 물질이므로, 염증성 질환의 예방 또는 치료를 위한 조성물의 유효성분으로서 유용하게 사용할 수 있다.The present invention relates to a composition for the prevention and treatment of inflammatory diseases containing a fraction prepared from Glehnia littoralis extract as an active ingredient, and more specifically, the fraction prepared by fractionating the liberation wind extract with an organic solvent is an inflammatory cytosol. It inhibits the production or secretion of the Caine interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), and is a safe material without cytotoxicity, so it is possible to It can be usefully used as an active ingredient of a composition for prevention or treatment.
Description
본 발명은 염증성 질환의 예방 및 치료용 조성물에 관한 것이다.
The present invention relates to a composition for the prevention and treatment of inflammatory diseases.
염증은 조직의 손상, 외부의 자극 또는 다양한 감염원에 대한 생체조직의 방어 반응의 하나로, 혈관과 체액 내의 각종 염증 매개 인자 및 다양한 면역 세포의 유기적 상호작용으로 인한 효소 활성화, 염증매개물질 분비, 세포 침윤 및 체액 삼출, 순환 장애, 조직의 변질과 과증식 등 일련의 복합적인 병리 현상이다. 염증반응의 과정은, 초기에 대식세포가 상처부위로 모여들어 침입한 세균을 공격한 후, 상처부위에 혈장이 축적되고 혈류가 증가되어 발열, 홍반, 부종, 통증 현상 등의 외적 증상이 일어나게 된다. 이러한 염증반응이 지속적으로 또는 과도하게 일어나면 오히려 질환의 주요 병리현상(과민성 알레르기 질환, 만성 염증 질환)으로 진행되며, 심각한 이상 장애를 초래하게 된다.
Inflammation is one of tissue damage, an external stimulus, or a protective response of biological tissues to various infectious agents. Enzyme activation, inflammatory mediator secretion, cell infiltration due to organic interaction of various inflammatory mediators and various immune cells in blood vessels and body fluids And a series of complex pathologies, including fluid effusion, circulatory disorders, tissue degeneration and hyperproliferation. In the inflammatory process, macrophages initially gather into the wound and attack the invading bacteria, and then plasma builds up in the wound and increases blood flow, causing external symptoms such as fever, erythema, edema, and pain. . If these inflammatory reactions occur continuously or excessively, the disease progresses to the main pathology of the disease (sensitized allergic disease, chronic inflammatory disease) and causes serious abnormal disorders.
생체에 있어서 염증의 발생 원인으로서는 다양한 생화학적인 현상이 관여하고 있다. 대식세포(macrophage)는 다양한 기능을 가진 세포로 화학적 자극에 의하여 여러 가지 사이토카인(cytokine)과 질소산화물(nitric oxide, NO)를 생성하여 염증반응에서 중요한 역할을 한다. 특히 대식세포에서 지질다당류(lipopolysaccharide, LPS)나 인터페론-γ, 종양괴사인자-α(tumor necrosis factor-α, TNF-α)와 같은 사이토카인 자극에 의해 발현되는 유도성 질소산화물 합성효소(inducible nitric oxide synthase, iNOS)는 장시간 동안 다량의 NO를 생산한다. 이러한 산화적 스트레스는 IκB에 의하여 억제되어 있는 염증반응의 전사인자인 NFκB 활성을 촉진시키는 것으로 알려져 있다. 활성화된 NFκB는 핵으로 이동하여 iNOS, COX-2 및 인터루킨-1β(interleukin-1β, IL-1β)나 TNF-α와 같은 여러 종류의 사이토카인 등 염증반응을 유도하는 유전자 발현을 촉진시키는 것으로 알려져 있으며, 이들 인자들을 저해하면 염증반응이 억제되는 것으로 알려져 있다(Baeuerle et al., Annu. Rev. Immunol., 12:141-179, 1994). 따라서, TNF-α, NO, 프로스타글란딘 또는 IL-1β의 생성을 억제하는 물질을 탐색하면, 부종 또는 피부염과 같은 염증성 질환에 효과적인 물질로 판명할 수 있을 것이다.
Various biochemical phenomena are involved as a cause of inflammation in living bodies. Macrophage (macrophage) is a cell with a variety of functions to produce various cytokines and nitric oxide (NO) by chemical stimulation plays an important role in the inflammatory response. Inducible nitric acidase, especially expressed by cytokine stimulation such as lipopolysaccharide (LPS), interferon-γ, and tumor necrosis factor-α (TNF-α) in macrophages oxide synthase (iNOS) produces large amounts of NO over long periods of time. This oxidative stress is known to promote NFκB activity, a transcription factor of the inflammatory response inhibited by IκB. Activated NFκB is known to migrate to the nucleus and stimulate the expression of genes that induce inflammatory responses, such as iNOS, COX-2 and several cytokines such as interleukin-1β and IL-1β or TNF-α. Inhibition of these factors is known to inhibit the inflammatory response (Baeuerle et al. , Annu. Rev. Immunol., 12: 141-179, 1994). Therefore, the search for a substance that inhibits the production of TNF-α, NO, prostaglandin or IL-1β may prove to be an effective substance for inflammatory diseases such as edema or dermatitis.
대부분의 염증 질환의 치료제로서 널리 사용되고 있는 제제인 비스테로이드성 소염제(non-steroidal anti-inflammatory drugs, NSAIDS)는 시클로옥시게나제(cyclooxygenase, COX)라고 하는 아라키돈산(arachidonic acid)로부터 프로스타글란딘(prostaglandin)의 생합성에 관여하는 효소 활성을 억제함으로써, 항염증 작용을 나타내는데, 주 치료작용 외에 위장관 장애, 간장애, 신장애 등의 심각한 부작용을 야기하기므로 장기간의 사용에 있어서 제약이 따르는 실정이다(Rajakariar R et al. 2006). 따라서 부작용이 거의 없어 장기간 사용하는데 무리가 없으면서 항염증 효능에 탁월한 새로운 소염 진통제의 개발이 널리 요구되고 있으며, 이는 최근 천연 자원으로부터의 효능 검증을 통한 소재 개발 연구가 활성화되고 있는 이유이기도 하다.
Non-steroidal anti-inflammatory drugs (NSAIDS), a widely used drug for the treatment of most inflammatory diseases, are produced from prostaglandin from arachidonic acid called cyclooxygenase (COX). By inhibiting the enzyme activity involved in the biosynthesis of the drug, it exhibits anti-inflammatory action, which causes serious side effects such as gastrointestinal disorders, liver disorders, and renal disorders in addition to the main therapeutic effects, and thus is restricted in long-term use (Rajakariar R et. al. 2006). Therefore, the development of a new anti-inflammatory analgesic that is excellent in anti-inflammatory efficacy without any difficulty for long-term use with little side effects is widely required, which is also a reason for the recent active research on material development through verification of efficacy from natural resources.
한약재 해방풍((海防風)은 산형과에 속하는 갯방풍(珊瑚菜, Glehnia littoralis)의 뿌리로, 북사삼이라고 불린다. 대표적인 보음약(補陰藥)인 사삼(沙參)은 그 기원식물의 종류가 많아 현재까지도 정리가 완료되지 않은 품목이다. 북사삼 즉, 해방풍은 보음약으로써의 효능이 남사삼보다 뛰어나다고 알려져 있어(주영승, 운곡본초학각론, 2004), 해열제, 진통제 등으로 사용되어 왔으며, 항산화, 항암, 항균, 항진균 등의 효능이 밝혀져 있다. 그러나 해방풍의 기원식물인 갯방풍은 희귀식물 및 보호종으로 지정될 정도로 자생 여건이 특수하여 국내에서의 재배는 전혀 이루어지지 않고 있다. The medicinal herb is the root of Glehnia littoralis belonging to the mountain family, and it is called Buksasam. It is known that Northsasam, or Haebangpung, is more effective than namsasam as a medicinal pill (Ju Young-seung, Ungok Herbalism, 2004), and has been used as an antipyretic, analgesic, etc. Antioxidant, anticancer, antibacterial, antifungal, etc. have been shown to be effective, but the native plant of the liberation wind, Gaetbangpung is a rare plant and protected species so designated as a natural native condition is not cultivated at all.
이에, 본 발명자들은 독성 및 부작용이 없는 천연물 유래의 염증성 질환용 약제를 개발하기 위해 연구하던 중, 해방풍 추출물을 유기용매로 분획하여 제조한 분획물이 해방풍 추출물에 비해 현저히 탁월한 사이토카인의 생산 및 분비를 억제하는 효능을 가지며, 세포독성이 없는 안전한 물질임을 확인함으로써, 염증성 질환의 예방 또는 치료용 조성물의 유효성분으로 사용될 수 있음을 밝힘으로써 본 발명을 완성하였다.
Thus, the inventors of the present invention while studying to develop a drug for inflammatory diseases derived from natural products without toxicity and side effects, the fraction produced by fractionation of the liberation wind extract with an organic solvent produced and secreted cytokine significantly superior to the liberation wind extract By confirming that it is a safe substance having no inhibitory effect and no cytotoxicity, the present invention has been completed by revealing that it can be used as an active ingredient for preventing or treating an inflammatory disease.
본 발명의 목적은 해방풍 추출물로부터 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방, 개선 또는 치료용 조성물을 제공하는 것이다.
It is an object of the present invention to provide a composition for the prevention, improvement or treatment of an inflammatory disease containing a fraction prepared from the Libyan wind extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 해방풍(Glehnia littoralis) 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for the prevention and treatment of inflammatory diseases containing a fraction prepared by fractionating Glehnia littoralis extract with an organic solvent as an active ingredient.
또한, 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 개선용 건강기능식품을 제공한다.In addition, it provides a health functional food for the prevention and improvement of inflammatory diseases containing a fraction prepared by dividing the liberation wind extract with an organic solvent as an active ingredient.
또한, 본 발명은 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 개선용 기능성 사료첨가제를 제공한다.In another aspect, the present invention provides a functional feed additive for the prevention and improvement of inflammatory diseases containing a fraction prepared by dividing the liberation wind extract with an organic solvent as an active ingredient.
아울러, 본 발명은 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 개선용 화장용 조성물을 제공한다.
In addition, the present invention provides a cosmetic composition for the prevention and improvement of inflammatory diseases containing a fraction prepared by fractionating the liberation wind extract with an organic solvent as an active ingredient.
본 발명의 해방풍(Glehnia littoralis) 추출물로부터 제조한 분획물은 염증성 매개체인 사이토카인의 생산 또는 분비를 해방풍 추출물에 비해 현저히 억제하는 탁월한 항염효과를 가지며, 세포독성이 없는 안전한 물질이므로, 염증성 질환의 예방 또는 치료를 위한 조성물의 유효성분으로 유용하게 사용할 수 있다.
Fractions prepared from Glehnia littoralis extract of the present invention have an excellent anti-inflammatory effect that significantly inhibits the production or secretion of cytokine, an inflammatory mediator, compared to Liberation wind extract, and is a safe substance without cytotoxicity, thus preventing or preventing inflammatory diseases. It can be usefully used as an active ingredient of a composition for treatment.
도 1은 본 발명의 해방풍 추출물 또는 이의 분획물의 세포독성을 나타내는 그래프이다:
70% EtOH Ex: 70% 에탄올 추출물;
Hx Fr: n-헥산 분획물;
MC Fr: 메틸렌클로라이드 분획물;
BuOH Fr: n-부탄올 분획물;
100% H20 Fr: 100% 물 분획물;
30% MeOH Fr: 30% 메탄올 분획물;
60% MeOH Fr: 60% 메탄올 분획물; 및
90% MeOH Fr: 90% 메탄올 분획물.
도 2는 본 발명의 해방풍 추출물 또는 이의 분획물의 인터루킨-1β(interleukin-1β, IL-1β) 생성 억제 효과를 나타내는 그래프이다.
도 3은 본 발명의 해방풍 추출물 또는 이의 분획물의 종양괴사인자-α(tumor necrosis factor-α, TNF-α) 생성 억제 효과를 나타내는 그래프이다.1 is a graph showing the cytotoxicity of haemul-pung extract or fractions thereof of the present invention:
70% EtOH Ex: 70% Ethanol Extract;
Hx Fr: n-hexane fraction;
MC Fr: methylene chloride fraction;
BuOH Fr: n-butanol fraction;
100%
30% MeOH Fr: 30% Methanol Fraction;
60% MeOH Fr: 60% methanol fractions; And
90% MeOH Fr: 90% Methanol Fraction.
Figure 2 is a graph showing the inhibitory effect of interleukin-1β (interleukin-1β, IL-1β) production of the Liberated wind extract or fractions thereof of the present invention.
Figure 3 is a graph showing the inhibitory effect of tumor necrosis factor-α (tumor necrosis factor-α, TNF-α) production of haebangpung extract or fractions thereof of the present invention.
이하, 본 발명에서 사용한 용어를 설명한다.
Hereinafter, terms used in the present invention will be described.
본 발명에서 사용되는 용어 "예방"은 본 발명의 조성물의 투여로 염증성 질환을 억제시키거나 진행을 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" means any action that inhibits or delays the progression of an inflammatory disease by administration of a composition of the present invention.
본 발명에서 사용되는 용어 "치료" 및 "개선"은 본 발명의 조성물의 투여로 염증성 질환이 호전 또는 이롭게 변경되는 모든 행위를 의미한다.As used herein, the terms "treatment" and "improvement" refer to any action in which an inflammatory disease is improved or beneficially altered by administration of a composition of the present invention.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.As used herein, the term "administration" means providing a subject with any of the compositions of the present invention in any suitable manner.
본 발명에서 사용되는 용어 "개체"는 본 발명의 조성물을 투여하여 염증성 질환이 호전될 수 있는 질환을 가진 인간, 원숭이, 개, 염소, 돼지 또는 쥐 등 모든 동물을 의미한다.As used herein, the term "individual" refers to any animal, such as a human, monkey, dog, goat, pig or rat, having a disease in which an inflammatory disease can be improved by administering the composition of the present invention.
본 발명에서 사용되는 용어 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜 또는 위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 이는 개체의 염증성 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출비율, 치료기간, 동시에 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.
As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, which includes the type, severity, activity of the drug, It may be determined according to the sensitivity to the drug, the time of administration, the route and rate of release, the duration of treatment, factors including the drug used at the same time and other factors well known in the medical field.
이하, 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 해방풍(Glehnia littoralis) 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물을 제공한다.The present invention provides a composition for the prevention and treatment of inflammatory diseases containing a fraction prepared by fractionating Glehnia littoralis extract with an organic solvent as an active ingredient.
상기 분획물은 해방풍 추출물을 n-헥산, 메틸렌클로라이드, 에틸아세테이트, n-부탄올 및 물로 순차적으로 계통 분획하여 수득한 n-헥산 분획물, 메틸렌클로라이드 분획물, 에틸아세테이트 분획물, n-부탄올 분획물 또는 물 분획물인 것이 바람직하고, n-헥산 분획물 또는 에틸아세테이트 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is n-hexane fraction, methylene chloride fraction, ethyl acetate fraction, n-butanol fraction or water fraction obtained by systematically partitioning the liberation extract from n-hexane, methylene chloride, ethyl acetate, n-butanol and water. Preferably, the n-hexane fraction or ethyl acetate fraction is more preferred, but is not limited thereto.
상기 분획물은 해방풍 추출물을 100% 물, 30% 메탄올, 60% 메탄올, 90% 메탄올 및 100% 메탄올로 순차적으로 계통 분획하여 수득한 100% 물 분획물, 30% 메탄올 분획물, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 바람직하고, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is 100% water fraction, 30% methanol fraction, 60% methanol fraction, 90% obtained by sequential fractionation of the liberation wind extract with 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol It is preferably a methanol fraction or a 100% methanol fraction, more preferably a 60% methanol fraction, a 90% methanol fraction or a 100% methanol fraction.
상기 분획물은 인터루킨-1β(interleukin-1β, IL-1β) 및 종양괴사인자-α(tumor necrosis factor-α, TNF-α)의 생성을 억제하는 것이 바람직하나 이에 한정하지 않는다.The fraction preferably inhibits the production of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), but is not limited thereto.
상기 염증성 질환은 피부염, 알레르기, 아토피, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통 (fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증, 및 급성 및 만성 염증 질환으로 이루어지는 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다.
The inflammatory diseases include dermatitis, allergy, atopic dermatitis, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia (fibromyalgia) ), Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, periarthritis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases It is preferably one of them, but is not limited thereto.
상기 해방풍 추출물 유래 분획물은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다:The liberation wind extract-derived fraction is preferably prepared by a manufacturing method comprising the following steps, but is not limited thereto:
1) 해방풍(Glehnia littoralis)에 추출용매를 가하여 추출하는 단계;1) extracting by adding an extraction solvent to Glehnia littoralis ;
2) 단계 1)의 추출물을 식힌 후 여과하는 단계;2) cooling the extract of step 1) and filtering;
3) 단계 2)의 여과된 추출물을 감압 농축한 후 건조하는 단계; 및3) drying the filtered extract of step 2) under reduced pressure and then drying; And
4) 단계 3)의 건조된 추출물에 유기용매를 극성에 따라 순차적으로 계통분획하는 단계.4) systematically fractionating organic solvents according to polarity in the dried extract of step 3).
상기 방법에 있어서, 단계 1)의 해방풍은 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 상기 해방풍은 전초, 잎, 줄기, 또는 뿌리를 모두 이용할 수 있고, 건조된 뿌리를 이용하는 것이 가장 바람직하나 이에 한정하지 않는다.In the above method, the liberation wind of step 1) can be used without limitation, such as cultivated or commercially available. The liberation wind can use all of the outpost, leaves, stems, or roots, it is most preferred to use the dried roots, but is not limited thereto.
상기 추출용매는 물, 알코올 또는 이들의 혼합물을 사용하는 것이 바람직하다. 상기 알코올로는 C1 내지 C4 저급 알코올을 이용하는 것이 바람직하고, 저급 알코올로는 에탄올 또는 메탄올을 이용하는 것이 바람직하며, 70% 에탄올을 이용하는 것이 더욱 바람직하나 이에 한정하지 않는다. 추출 방법으로는 열수추출, 침지추출, 환류냉각추출 및 초음파추출 등을 이용할 수 있으며, 열수추출 방법으로 1회 내지 5회 추출하는 것이 바람직하며, 3회 반복 추출하는 것이 더욱 바람직하나 이에 한정하지 않는다. 상기 추출용매는 건조된 해방풍 뿌리 중량에 5 내지 15배 첨가하여 추출하는 것이 바람직하고 10배 첨가하여 추출하는 것이 더욱 바람직하다. 추출온도는 40 내지 80℃인 것이 바람직하고 50 내지 60℃인 것이 더욱 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 2 내지 6시간인 것이 바람직하며, 2시간이 더욱 바람직하나 이에 한정하지 않는다. The extraction solvent is preferably water, alcohol or a mixture thereof. As the alcohol, it is preferable to use C 1 to C 4 lower alcohols, ethanol or methanol is preferably used as the lower alcohol, more preferably 70% ethanol, but is not limited thereto. As the extraction method, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used, and the extraction may be preferably performed one to five times by the hot water extraction method, and more preferably three times of extraction. . The extraction solvent is preferably extracted by adding 5 to 15 times the weight of the dried liberation wind roots, more preferably by adding 10 times. The extraction temperature is preferably 40 to 80 ° C and more preferably 50 to 60 ° C, but is not limited thereto. In addition, the extraction time is preferably 2 to 6 hours, more preferably 2 hours is not limited thereto.
상기 방법에 있어서, 단계 3)의 감압농축은 진공감압농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조를 모두 이용할 수 있으며, 이 중 동결건조하는 것이 바람직하나 이에 한정하지 않는다. In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. In addition, drying may be used under reduced pressure drying, vacuum drying, boiling drying, spray drying or lyophilization, preferably lyophilization, but is not limited thereto.
상기 방법에 있어서, 단계 4)의 계통분획은 n-헥산, 메틸렌클로라이드, 에틸아세테이트, n-부탄올 및 물로 순차적으로 계통분획하는 것이 바람직하나 이에 한정되지 않는다. 또한, 단계 4)의 계통분획은 100% 물, 30% 메탄올, 60% 메탄올, 90% 메탄올 및 100% 메탄올로 순차적으로 계통분획하는 것이 바람직하나 이에 한정되지 않는다.In the above method, the branched fraction of step 4) is preferably branched into n-hexane, methylene chloride, ethyl acetate, n-butanol and water, but is not limited thereto. In addition, the branched fraction of step 4) is preferably branched into 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol, but is not limited thereto.
상기 해방풍 추출물의 분획물은 해방풍 추출물에 추가로 용매를 가하여 분획물을 제조하는 단계를 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다. The fraction of the liberation wind extract is preferably prepared by a manufacturing method including the step of preparing a fraction by adding a solvent to the liberation wind extract is not limited thereto.
상기 분획물은 상기 해방풍 추출물로부터 분획 과정을 1 내지 5회, 바람직하게는 3회 반복하여 수득할 수 있고, 분획 후 감압 농축하는 것이 바람직하나 이에 한정하지 않는다.The fraction may be obtained by repeating the fractionation process 1 to 5 times, preferably three times from the liberation wind extract, preferably concentrated under reduced pressure after the fraction, but is not limited thereto.
본 발명의 구체적인 실시예에서, 해방풍 뿌리를 물로 세척한 후, 그늘 및 실온에서 7일간 건조시켰다. 건조된 해방풍 뿌리를 분쇄하여 추출용기에 넣고, 추출용매로 50 ~ 60℃에서 2시간 동안 추출하였다. 해방풍 추출물을 수득한 후, 거름종이 등을 이용하여 고형분을 제거하고 현탁액을 원심분리하여 상층액을 감압 여과하였다. 상기 추출액을 감압농축하고 동결건조시켜 해방풍 추출물을 제조하였다.In a specific embodiment of the present invention, the libido roots were washed with water and then dried for 7 days at shade and room temperature. The dried liberation wind roots were ground and put into an extraction container, and extracted with an extraction solvent at 50 ~ 60 ℃ for 2 hours. After the liberation wind extract was obtained, the solids were removed using a filter paper or the like, and the suspension was centrifuged to filter the supernatant under reduced pressure. The extract was concentrated under reduced pressure and lyophilized to produce a liberation extract.
본 발명의 구체적인 실시예에서, 상기 해방풍 추출물을 증류수에 현탁시킨 후, 극성을 달리하는 용매인 n-헥산, 메틸렌클로라이드, 에틸아세테이트, n-부탄올 및 물 순으로 계통 분획하고, 각 용매 분획물을 감압 농축하여 해방풍 추출물로부터 n-헥산 분획물, 메틸렌클로라이드 분획물, 에틸아세테이트 분획물, n-부탄올 분획물 및 물 분획물을 제조하였다. In a specific embodiment of the present invention, the liberated wind extract is suspended in distilled water, and then systematically fractionated in order of n-hexane, methylene chloride, ethyl acetate, n-butanol and water as solvents having different polarities, and each solvent fraction is decompressed. Concentration prepared n-hexane fraction, methylene chloride fraction, ethyl acetate fraction, n-butanol fraction and water fraction from the liberation extract.
본 발명의 구체적인 실시예에서, 상기 해방풍 추출물을 메탄올에 현탁시킨 후, 극성을 달리하는 용매인 물, 30% 메탄올, 60% 메탄올, 90% 메탄올 및 100% 메탄올 순으로 계통 분획하고, 각 용매 분획물을 감압 농축하여 해방풍 추출물로부터 100% 물 분획물, 30% 메탄올 분획물, 60% 메탄올 분획물, 90% 메탄올 분획물 및 100% 메탄올 분획물을 제조하였다.
In a specific embodiment of the present invention, the liberation wind extract is suspended in methanol, and then systematically fractionated in order of water, 30% methanol, 60% methanol, 90% methanol and 100% methanol, which are solvents having different polarities. The reaction mixture was concentrated under reduced pressure to prepare 100% water fraction, 30% methanol fraction, 60% methanol fraction, 90% methanol fraction and 100% methanol fraction from the liberation wind extract.
본 발명자들은 해방풍 추출물 또는 이의 분획물의 세포독성을 확인하기 위하여, 대식세포주에 상기 70% 에탄올 추출물 또는 이의 분획물을 처리하고 흡광도를 측정하여 세포생존율을 알아보았다. 그 결과, 해방풍 추출물 또는 분획물 모두 대조군과 비교하여 세포생존율의 현저한 차이가 없었다. 따라서, 본 발명의 해방풍 추출물의 분획물은 세포독성이 없는 안전한 물질임을 확인하였다(도 1 참조). The present inventors treated the 70% ethanol extract or a fraction thereof to the macrophage line in order to confirm the cytotoxicity of the Liberation wind extract or a fraction thereof to determine the cell survival rate. As a result, there was no significant difference in cell viability compared to the control group, liberation wind extract or fraction. Therefore, it was confirmed that the fraction of the liberation wind extract of the present invention is a safe substance without cytotoxicity (see FIG. 1).
또한, 본 발명자들은 해방풍 추출물 또는 이의 분획물의 염증 억제 효과를 확인하기 위하여, 대식세포주를 대상으로 염증유발 사이토카인(cytokine)인 인터루킨1β(interleukin-1β, IL-1β) 및 종양괴사인자(tumor necrosis factor-α, TNF-α)의 생성 억제 효과를 알아보았다. 그 결과, 해방풍 추출물 또는 이의 분획물은 IL-1β 및 TNF-α의 생산 및 분비를 억제하였고, 특히, 해방풍 추출물과 비교하여 해방풍 추출물의 분획물에서 염증성 사이토카인의 생성 억제 활성이 현저히 뛰어난 것으로 나타났다(도 2 내지 도 3 참조). 구체적으로, IL-1β의 생성 억제 효과의 경우, 상기 분획물은 추출물에 비해 약 40 ~ 5배 우수하였으며, TNF-α의 생성 억제 효과의 경우, 상기 분획물은 추출물에 비해 약 30 ~ 5배 우수하였다.In addition, the inventors of the present invention, in order to confirm the inhibitory effect of the extracts of the Liberation wind extract or fractions thereof, interleukin 1β (interleukin-1β, IL-1β) and tumor necrosis, a cytokine-induced cytokine in macrophage lines factor-α, TNF-α) production inhibition effect was examined. As a result, the liberation extract or fractions thereof inhibited the production and secretion of IL-1β and TNF-α, and in particular, the inhibitory activity of the production of inflammatory cytokines in the fraction of liberation extract was significantly superior to that of the release extract. 2 to 3). Specifically, in the case of the inhibitory effect of the production of IL-1β, the fraction was about 40 to 5 times better than the extract, and in the case of the inhibitory effect of TNF-α, the fraction was about 30 to 5 times superior to the extract. .
따라서, 본 발명의 해방풍 추출물 유래 분획물은 항염작용 활성을 가지며, 특히, 해방풍 추출물에 비해 현저히 뛰어난 염증 억제 효과가 있음을 확인하였다. 그러므로, 본 발명에 따른 해방풍 추출물로부터 제조된 분획물은 염증성 질환의 예방 및 치료용 조성물의 유효성분으로서 유용하게 사용될 수 있음을 알 수 있다.
Therefore, it is confirmed that the fractions derived from the liberation wind extract of the present invention have anti-inflammatory activity, and in particular, the anti-inflammatory effect is significantly superior to the liberation wind extract. Therefore, it can be seen that the fraction prepared from the liberation wind extract according to the present invention can be usefully used as an active ingredient of the composition for the prevention and treatment of inflammatory diseases.
본 발명의 해방풍 추출물 유래 분획물을 포함하는 염증성 질환 예방 및 치료용 약학적 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition for preventing and treating inflammatory diseases comprising a fraction derived from the liberation extract of the present invention is powder, granules, tablets, capsules, suspensions, emulsions, syrups and the like, oral formulations, suppositories, and the like, according to a conventional method. It can be formulated and used in the form of sterile injectable solutions.
경구투여를 위한 고형제제에는 산제, 과립제, 정제, 캡슐제, 연질캅셀제, 환 등이 포함된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제로는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 멸균된 수용액, 액제, 비수성용제, 현탁제, 에멀젼, 시럽, 좌제, 에어로졸 등의 외용제 및 멸균 주사제제의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학적 조성물을 제조하여 사용할 수 있으나, 이에 한정하지 않는다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol 약학폴리에틸렌 글리콜약학올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Solid form preparations for oral administration include powders, granules, tablets, capsules, soft capsules, and the like. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include powders, granules, tablets, capsules, sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc. It may be used in the form of a formulation, and preferably, an external skin pharmaceutical composition of cream, gel, patch, spray, ointment, warning agent, lotion agent, linen agent, pasta agent or cataplasma agent may be prepared and used. It is not limited to this. Non-aqueous solvents and suspending agents may be used as vegetable oils such as propylene glycol pharmaceutical polyethylene glycol pharmaceutical olive oil, injectable esters such as ethyl oleate, etc. As a base of suppositories, witepsol, macrogol, Tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명에 따른 약학적 조성물은 통상적으로 사용되는 담체, 부형제, 붕해제, 감미제, 활택제, 향미제 및 희석제등을 추가로 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 상기 붕해제로는 전분글리콜산나트륨, 크로스포비돈, 크로스카멜로스나트륨, 알긴산, 카르복시메틸셀룰로오스 칼슘, 카르복시 메틸셀룰로오스 나트륨, 키토산, 구아검, 저치환도히드록시프로필셀룰로오스, 마그네슘 알루미늄 실리케이트, 폴라크릴린 칼륨 등이 있다.The pharmaceutical composition according to the present invention may further include conventionally used carriers, excipients, disintegrants, sweeteners, lubricants, flavoring agents and diluents. The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The disintegrants include sodium starch glycolate, crospovidone, croscarmellose sodium, alginic acid, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, chitosan, guar gum, low-substituted hydroxypropyl cellulose, magnesium aluminum silicate, and polyacryline Potassium and the like.
또한, 본 발명에 따른 약학적 조성물은 약제학적으로 허용가능한 첨가제를 추가적으로 포함할 수 있으며, 이때 약제학적으로 허용가능한 첨가제로는 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바 납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당, 덱스트로스, 소르비톨, 탈크 등이 사용될 수 있다. 본 발명에 따른 약제학적으로 허용가능한 첨가제는 상기 약학적 조성물에 대해 0.1 ~ 90 중량부 포함되는 것이 바람직하다.In addition, the pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, Calcium hydrogen phosphate, lactose, mannitol, malt, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opadry, sodium starch glycolate, carnauba lead, synthetic aluminum silicate, stearic acid, magnesium stearate, Aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, talc and the like can be used. The pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the pharmaceutical composition.
본 발명의 약학적 조성물은 상기 해방풍 추출물 유래 분획물 성분에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 본 발명의 조성물은, 조성물 총 중량에 대하여 상기 본 발명의 분획물을 0.0001 내지 10 중량%로, 바람직하게는 0.001 내지 1 중량%를 포함할 수 있다.The pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in addition to the fractions derived from the liberation wind extract. The composition of the present invention may comprise from 0.0001 to 10% by weight, preferably 0.001 to 1% by weight of the fraction of the present invention based on the total weight of the composition.
본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 피부 외용 또는 복강내주사, 직장내주사, 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and when parenteral administration is selected by external skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method. desirable.
본 발명의 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 그 범위가 다양하며, 일일 투여량은 해방풍 추출물의 양을 기준으로 0.0001 내지 100 ㎎/㎏이고, 바람직하게는 0.001 내지 10 ㎎/㎏이며, 하루 1 ~ 6 회 투여될 수 있다. The dosage of the composition of the present invention varies depending on the weight, age, sex, health status, diet, time of administration, method of administration, excretion rate and severity of the disease of the patient, the daily dosage is the amount of liberation wind extract 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, and may be administered 1 to 6 times per day.
본 발명의 조성물은 염증성 질환의 예방 또는 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.
The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention or treatment of inflammatory diseases.
또한, 본 발명은 약학적으로 유효한 양의 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 염증성 질환에 걸린 개체에 투여하는 단계를 포함하는 염증성 질환 치료 방법을 제공한다.In addition, the present invention provides a method for treating inflammatory diseases comprising administering to a subject suffering from an inflammatory disease a fraction prepared by fractionating a pharmaceutically effective amount of a liberation extract with an organic solvent.
또한, 본 발명은 약학적으로 유효한 양의 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 개체에 투여하는 단계를 포함하는 염증성 질환 예방 방법을 제공한다.In another aspect, the present invention provides a method for preventing inflammatory disease comprising administering to the subject a fraction prepared by fractionating a pharmaceutically effective amount of the liberation extract with an organic solvent.
상기 개체는 척추동물이고 바람직하게는 포유동물이며, 그보다 바람직하게는 쥐, 토끼, 기니아피크, 햄스터, 개, 고양이와 같은 실험동물이고, 가장 바람직하게는 침팬지, 고릴라와 같은 유인원류 동물이다.The subject is a vertebrate and preferably a mammal, more preferably an experimental animal such as a rat, rabbit, guinea pig, hamster, dog, cat, and most preferably an ape-like animal such as a chimpanzee or gorilla.
상기 투여방법은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 복강내주사, 직장내주사, 피하주사, 정맥주사, 근육내 주사, 자궁내 경막 주사, 뇌혈관내(intracerebroventricular) 주사 또는 흉부내 주사에 의해 투여될 수 있다.The method of administration may be administered orally or parenterally, intraperitoneal, rectal, subcutaneous, intravenous, intramuscular, intrauterine dural, intracerebroventricular or intrathoracic It can be administered by injection.
상기 약학적으로 유효한 양이란 0.0001 내지 100 ㎎/㎏이고, 바람직하게는 0.001 내지 10 ㎎/㎏이며, 이에 한정하지 않는다. 투여량은 특정 환자의 체중, 연령, 성별, 건강상태, 식이, 투여기간, 투여방법, 제거율, 질환의 중증도 등에 따라 변화될 수 있다.The pharmaceutically effective amount is 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, but is not limited thereto. The dose may vary depending on the weight, age, sex, health condition, diet, administration period, method of administration, rate of elimination, severity of disease, and the like of a particular patient.
상기 염증성 질환은 피부염, 알레르기, 아토피, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통 (fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증, 및 급성 및 만성 염증 질환으로 이루어지는 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다.The inflammatory diseases include dermatitis, allergy, atopic dermatitis, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia (fibromyalgia) ), Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, periarthritis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases It is preferably one of them, but is not limited thereto.
본 발명의 해방풍 추출물로부터 제조된 분획물은 염증성 사이토카인인, 인터루킨-1β(interleukin-1β, IL-1β) 및 종양괴사인자-α(tumor necrosis factor-α, TNF-α)의 생산 또는 분비를 억제하는 세포독성이 없는 안전한 물질이므로, 염증성 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
Fractions prepared from the liberation extracts of the present invention inhibit the production or secretion of inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) Since it is a safe substance without cytotoxicity, it can be usefully used for the prevention or treatment of inflammatory diseases.
또한, 본 발명은 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for the prevention and improvement of inflammatory diseases containing a fraction prepared by dividing the liberation wind extract with an organic solvent as an active ingredient.
상기 분획물은 해방풍 추출물을 n-헥산, 메틸렌클로라이드, 에틸아세테이트, n-부탄올 및 물로 순차적으로 계통 분획하여 수득한 n-헥산 분획물, 메틸렌클로라이드 분획물, 에틸아세테이트 분획물, n-부탄올 분획물 또는 물 분획물인 것이 바람직하고, n-헥산 분획물 또는 에틸아세테이트 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is n-hexane fraction, methylene chloride fraction, ethyl acetate fraction, n-butanol fraction or water fraction obtained by systematically partitioning the liberation extract from n-hexane, methylene chloride, ethyl acetate, n-butanol and water. Preferably, the n-hexane fraction or ethyl acetate fraction is more preferred, but is not limited thereto.
상기 분획물은 해방풍 추출물을 100% 물, 30% 메탄올, 60% 메탄올, 90% 메탄올 및 100% 메탄올로 순차적으로 계통 분획하여 수득한 100% 물 분획물, 30% 메탄올 분획물, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 바람직하고, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is 100% water fraction, 30% methanol fraction, 60% methanol fraction, 90% obtained by sequential fractionation of the liberation wind extract with 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol It is preferably a methanol fraction or a 100% methanol fraction, more preferably a 60% methanol fraction, a 90% methanol fraction or a 100% methanol fraction.
상기 염증성 질환은 피부염, 알레르기, 아토피, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통 (fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증, 및 급성 및 만성 염증 질환으로 이루어지는 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다.The inflammatory diseases include dermatitis, allergy, atopic dermatitis, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia (fibromyalgia) ), Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, periarthritis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases It is preferably one of them, but is not limited thereto.
본 발명의 해방풍 추출물로부터 제조된 분획물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The fraction prepared from the liberation extract of the present invention can be added as it is or used with other food or food ingredients, and can be suitably used according to conventional methods.
상기 식품의 종류에는 특별한 제한은 없다. 상기 분획물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the food to which the fraction can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, drinks, Alcoholic beverages and vitamin complexes, etc., includes all of the health food in the conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 0.01 ~ 0.04 g, 바람직하게는 약 0.02 ~ 0.03 g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 해방풍 추출물의 분획물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the fractions of the liberation wind extract of the present invention are various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명의 해방풍 추출물로부터 제조된 분획물은 염증성 사이토카인인, 인터루킨-1β(interleukin-1β, IL-1β) 및 종양괴사인자-α(tumor necrosis factor-α, TNF-α)의 생산 또는 분비를 억제하고 세포독성이 없는 안전한 물질이므로, 염증성 질환의 예방 또는 개선용 건강기능식품에 유용하게 사용될 수 있다.
Fractions prepared from the liberation extracts of the present invention inhibit the production or secretion of inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) Since it is a safe substance with no cytotoxicity, it can be usefully used for health food for preventing or improving inflammatory diseases.
또한, 본 발명은 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 개선용 기능성 사료첨가제를 제공한다.In another aspect, the present invention provides a functional feed additive for the prevention and improvement of inflammatory diseases containing a fraction prepared by dividing the liberation wind extract with an organic solvent as an active ingredient.
상기 분획물은 해방풍 추출물을 n-헥산, 메틸렌클로라이드, 에틸아세테이트, n-부탄올 및 물로 순차적으로 계통 분획하여 수득한 n-헥산 분획물, 메틸렌클로라이드 분획물, 에틸아세테이트 분획물, n-부탄올 분획물 또는 물 분획물인 것이 바람직하고, n-헥산 분획물 또는 에틸아세테이트 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is n-hexane fraction, methylene chloride fraction, ethyl acetate fraction, n-butanol fraction or water fraction obtained by systematically partitioning the liberation extract from n-hexane, methylene chloride, ethyl acetate, n-butanol and water. Preferably, the n-hexane fraction or ethyl acetate fraction is more preferred, but is not limited thereto.
상기 분획물은 해방풍 추출물을 100% 물, 30% 메탄올, 60% 메탄올, 90% 메탄올 및 100% 메탄올로 순차적으로 계통 분획하여 수득한 100% 물 분획물, 30% 메탄올 분획물, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 바람직하고, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is 100% water fraction, 30% methanol fraction, 60% methanol fraction, 90% obtained by sequential fractionation of the liberation wind extract with 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol It is preferably a methanol fraction or a 100% methanol fraction, more preferably a 60% methanol fraction, a 90% methanol fraction or a 100% methanol fraction.
상기 염증성 질환은 피부염, 알레르기, 아토피, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통비강직성 척추염, 류마티스 열, 루푸스, 섬유근통 (fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증, 및 급성 및 만성 염증 질환으로 이루어지는 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다.The inflammatory diseases include dermatitis, allergies, atopic dermatitis, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, analgesic spondylitis, rheumatic fever, lupus, fibromyalgia , Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases One is preferred but not limited thereto.
상기 사료첨가제는 가금류, 가축 등에게 꾸준히 섭취하게 함으로써 염증을 예방할 수 있고, 이미 발생한 염증을 치료할 수 있다. The feed additives can be prevented by steadily ingesting poultry, livestock, and the like, and can treat inflammation that has already occurred.
본 발명의 사료첨가제에는 상기 해방풍 추출물의 분획물이 0.1 ~ 20% 중량부, 지방분해효소(lipase)가 0.001 ~ 0.01% 중량부, 제3인산칼슘이 1 ~ 20% 중량부, 비타민E가 0.01 ~ 0.1% 중량부, 효소분말이 1 ~ 10% 중량부, 유산균이 0.1 ~ 10% 중량부, 바실러스(bacillus) 배양액이 0.01 ~ 10% 중량부 및 포도당은 20 ~ 90% 중량부로 구성되어 있는 것이 바람직하나, 특별히 이에 한정하지 않으며, 해방풍 추출물의 분획물이 유효량으로 첨가되어 있다면, 본 발명의 사료첨가제로서 이용 가능하다. In the feed additive of the present invention, 0.1 to 20% by weight of the fraction of the liberation wind extract, 0.001 to 0.01% by weight of lipase, 1 to 20% by weight of tricalcium phosphate, and 0.01 to 0.01% of vitamin E. 0.1 parts by weight, enzyme powder 1 to 10% by weight, lactic acid bacteria 0.1 to 10% by weight, Bacillus (Bacillus) culture medium is preferably composed of 0.01 to 10% by weight and
상기 유효량이란, 가금류, 가축 등이 꾸준히 섭취하게 함으로써 염증성 질환을 예방하거나, 이미 발생한 염증성 질환을 치료할 수 있는 양을 의미한다. 또한, 첨가에 의한 이익을 넘는 악영향이 생기지 않는 양이 바람직하다.The effective amount means an amount capable of preventing inflammatory diseases or treating inflammatory diseases that have already occurred by allowing poultry, livestock, etc. to be continuously ingested. Moreover, it is preferable that the quantity which does not produce the bad influence beyond the benefit by addition is preferable.
또한, 상기 사료첨가제는 추가적으로 가금류 및 가축 등에 허용되는 담체를 함유할 수 있다. 본 발명에 있어서는 상기 사료첨가제를 그대로 또는 공지의 담체, 안정제 등을 가할 수 있으며, 필요에 따라 비타민, 아미노산류, 미네랄 등의 각종 양분, 항산화제, 항생물질, 항균제 및 기타의 첨가제 등을 가할 수도 있으며, 그 형상으로서는 분체, 과립, 펠릿, 현탁액 등의 적당한 상태일 수 있다. 본 발명의 사료첨가제를 공급하는 경우는 가금류 및 가축 등에 대하여 단독으로 또는 사료에 혼합하여 공급할 수 있다. In addition, the feed additive may additionally contain a carrier that is acceptable to poultry and livestock. In the present invention, the feed additive may be added as it is or a known carrier, stabilizer and the like, and various nutrients such as vitamins, amino acids and minerals, antioxidants, antibiotics, antibacterial agents and other additives may be added as necessary. The shape may be in a suitable state such as powder, granules, pellets, suspension, or the like. When supplying the feed additive of the present invention can be supplied alone or mixed in the feed for poultry and livestock.
본 발명의 해방풍 추출물로부터 제조된 분획물은 염증성 사이토카인인, 인터루킨-1β(interleukin-1β, IL-1β) 및 종양괴사인자-α(tumor necrosis factor-α, TNF-α)의 생산 또는 분비를 억제하고 세포독성이 없는 안전한 물질이므로, 염증성 질환의 예방 또는 개선용 기능성 사료첨가제에 유용하게 사용될 수 있다.
Fractions prepared from the liberation extracts of the present invention inhibit the production or secretion of inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) Because it is a safe substance without cytotoxicity, it can be usefully used in functional feed additives for the prevention or improvement of inflammatory diseases.
아울러, 본 발명은 해방풍 추출물을 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 개선용 화장용 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for the prevention and improvement of inflammatory diseases containing a fraction prepared by fractionating the liberation wind extract with an organic solvent as an active ingredient.
상기 분획물은 해방풍 추출물을 n-헥산, 메틸렌클로라이드, 에틸아세테이트, n-부탄올 및 물로 순차적으로 계통 분획하여 수득한 n-헥산 분획물, 메틸렌클로라이드 분획물, 에틸아세테이트 분획물, n-부탄올 분획물 또는 물 분획물인 것이 바람직하고, n-헥산 분획물 또는 에틸아세테이트 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is n-hexane fraction, methylene chloride fraction, ethyl acetate fraction, n-butanol fraction or water fraction obtained by systematically partitioning the liberation extract from n-hexane, methylene chloride, ethyl acetate, n-butanol and water. Preferably, the n-hexane fraction or ethyl acetate fraction is more preferred, but is not limited thereto.
상기 분획물은 해방풍 추출물을 100% 물, 30% 메탄올, 60% 메탄올, 90% 메탄올 및 100% 메탄올로 순차적으로 계통 분획하여 수득한 100% 물 분획물, 30% 메탄올 분획물, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 바람직하고, 60% 메탄올 분획물, 90% 메탄올 분획물 또는 100% 메탄올 분획물인 것이 더욱 바람직하나 이에 한정하지 않는다.The fraction is 100% water fraction, 30% methanol fraction, 60% methanol fraction, 90% obtained by sequential fractionation of the liberation wind extract with 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol It is preferably a methanol fraction or a 100% methanol fraction, more preferably a 60% methanol fraction, a 90% methanol fraction or a 100% methanol fraction.
상기 염증성 질환은 피부염, 알레르기, 아토피, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통 (fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증, 및 급성 및 만성 염증 질환으로 이루어지는 군으로부터 선택되는 어느 하나인 것이 바람직하고 부종 또는 피부염인 것이 더욱 바람직하나 이에 한정하지 않는다.The inflammatory diseases include dermatitis, allergy, atopic dermatitis, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia (fibromyalgia) ), Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, periarthritis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases It is preferably any one, more preferably edema or dermatitis, but is not limited thereto.
본 발명의 해방풍 추출물의 분획물을 유효성분으로 함유하여 제조되는 화장품은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. 유화 제형의 화장품으로는 영양화장수, 크림, 에센스 등이 있으며, 가용화 제형의 화장품으로는 유연화장수가 있다. 적합한 화장품의 제형으로는 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.Cosmetics prepared by containing a fraction of the liberation wind extract of the present invention as an active ingredient can be prepared in the form of a general emulsion formulation and solubilized formulation. Cosmetics of emulsified form include nutrition lotion, cream, essence, etc., and cosmetics of solubilized form have softening longevity. Suitable cosmetic formulations include, for example, solutions, gels, solid or kneaded anhydrous products, emulsions obtained by dispersing the oil phase in water, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) In the form of a dispersing agent, in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a conical stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
또한, 상기 화장품은 본 발명의 추출물의 분획물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. In addition to the fractions of the extract of the present invention, the cosmetics, in addition to fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, Commonly used in water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics And any other ingredients that may be used, such as auxiliaries commonly used in the cosmetic field.
본 발명의 해방풍 추출물로부터 제조된 분획물은 염증성 사이토카인인, 인터루킨-1β(interleukin-1β, IL-1β) 및 종양괴사인자-α(tumor necrosis factor-α, TNF-α)의 생산 또는 분비를 억제하고 세포독성이 없는 안전한 물질이므로, 염증성 질환의 예방 또는 개선용 화장용 조성물에 유용하게 사용될 수 있다.
Fractions prepared from the liberation extracts of the present invention inhibit the production or secretion of inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) And because it is a safe material without cytotoxicity, it can be usefully used in the cosmetic composition for the prevention or improvement of inflammatory diseases.
이하, 본 발명을 실시예 및 제조예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples and Production Examples.
단, 하기 실시예 및 제조예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 제조예에 한정되는 것은 아니다.
However, the following Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Preparation Examples.
<실시예 1> 해방풍 추출물의 제조Example 1 Preparation of Liberation Wind Extract
강원도 고성군에서 채집한 해방풍(Glehnia littoralis)의 뿌리를 건조한 후 분쇄하였다. 상기 방법으로 준비한 해방풍 100 g을 1 ℓ의 70% 에탄올수용액(70% EtOH), 100% 에탄올(100% EtOH), 100% 메탄올(100% MeOH) 및 물(H2O)에 각각 침지하여 교반한 다음, 열을 가해 50 내지 60℃를 유지하는 추출온도에서 2시간 동안 환류 추출하고 여과지에 여과하였다. 상기 추출액을 50 내지 55℃에서 농축기를 사용하여 감압 농축한 후, 동결 건조시켜 해방풍 70% 에탄올, 100% 에탄올, 100% 메탄올 및 물 추출물을 제조하였다. The roots of Glehnia littoralis collected in Goseong-gun, Gangwon-do were dried and ground. 100 g of the liberated wind prepared by the above method was immersed in 1 L of 70% ethanol aqueous solution (70% EtOH), 100% ethanol (100% EtOH), 100% methanol (100% MeOH) and water (H 2 O), respectively. Then, the mixture was heated to reflux for 2 hours at an extraction temperature maintained at 50 to 60 ° C. and filtered through a filter paper. The extract was concentrated under reduced pressure using a concentrator at 50 to 55 ° C., and then freeze-dried to prepare a
그 결과, 각각 70% 에탄올 수용액(4.5 g), 100% 에탄올(5 g), 100% 메탄올(5 g), 물(8 g)의 해방풍 용매 추출물을 수득하였다.
As a result, liberated wind solvent extracts of 70% aqueous ethanol (4.5 g), 100% ethanol (5 g), 100% methanol (5 g) and water (8 g) were obtained, respectively.
<실시예 2> 해방풍 추출물로부터 분획물의 제조Example 2 Preparation of Fractions from Liberated Wind Extracts
<2-1> 유기용매 분획물의 제조<2-1> Preparation of Organic Solvent Fraction
상기 해방풍 추출물로부터 분획물을 제조하기 위하여, 상기 <실시예 1>의 방법에 따라 5.6 ㎏의 건조된 해방풍 뿌리로부터 70% 에탄올수용액 추출물 238 g을 수득하였다. 상기 추출물 238 g을 0.8 ℓ의 물(H2O)에 현탁한 후, 다시 현탁액과 동량의 n-헥산(n-hexane, Hx)을 가하고 물층과 Hx층으로 분리되도록 방치하였다. 화학평형이 이루어진 후, Hx층을 분리하고 다시 새로운 동량의 Hx를 부어서 물층과 Hx층으로 분리되도록 방치하였다. 상기 층 분리 과정을 3회 반복하여 수득한 Hx층을 감압 농축하여 Hx 분획물(54.8 g)을 수득하였다. 상기와 동일한 방법으로, Hx 분획물을 분리하고 남은 물층에 용매의 극성에 따라 메틸렌클로라이드(methylene chloride, dichloromethane, MC), 에틸아세테이트(ethyl acetate, EA), n-부탄올(n-butanol, BuOH), 물(H2O) 순으로 계통 분획 추출을 함으로써 해방풍 메틸렌클로라이드, 에틸아세테이트, n-부탄올 및 물 분획물을 제조하였다.In order to prepare a fraction from the liberation extract, 238 g of a 70% ethanol aqueous solution extract was obtained from 5.6 kg of dried liberation wind according to the method of <Example 1>. 238 g of the extract was suspended in 0.8 L of water (H 2 O), and the suspension and the same amount of n-hexane (n-hexane, Hx) were added thereto and allowed to separate into the water layer and the Hx layer. After chemical equilibrium was established, the Hx layer was separated, and a new amount of Hx was poured again and allowed to separate into the water layer and the Hx layer. The Hx layer obtained by repeating the above layer separation process three times was concentrated under reduced pressure to obtain an Hx fraction (54.8 g). In the same manner as above, the Hx fractions were separated and the remaining water layer was separated from methylene chloride (methylene chloride, dichloromethane, MC), ethyl acetate (EA), n-butanol (n-butanol, BuOH), Liberation wind methylene chloride, ethyl acetate, n-butanol and water fractions were prepared by extracting the system fractions in the order of water (H 2 O).
그 결과, 각각 MC(7 g), EA(15.4 g), BuOH(14.1 g) 및 H2O(102.6 g) 해방풍 분획물을 수득하였다.
As a result, MC (7 g), EA (15.4 g), BuOH (14.1 g) and H 2 O (102.6 g) liberation wind fractions were obtained, respectively.
<2-2> 메탄올 분획물의 제조<2-2> Preparation of Methanol Fractions
상기 해방풍 추출물로부터 분획물을 제조하기 위하여, 상기 <실시예 1>의 방법에 따라 1.1 ㎏의 건조된 해방풍 뿌리로부터 70% 에탄올수용액 추출물 50 g을 수득하였다. 상기 추출물 50 g을 0.25 ℓ의 메탄올(MeOH)에 현탁한 후, Amberlite XAD-4를 이용하여 100% 물(100% H2O)과 각기 다른 비율(30%, 60%, 90% 및 100%)의 메탄올 순으로 분획 추출을 실시하여, 100% 물 분획물(100% H2O, 42 g), 30% MeOH 분획물(30% MeOH, 0.89 g), 60% MeOH 분획물(60% MeOH, 1 g), 90% MeOH 분획물(90% MeOH, 2.3g), 100% MeOH 분획물(100% MeOH, 1.2 g)을 각각 수득하였다.
In order to prepare a fraction from the liberation extract, 50 g of 70% ethanol aqueous solution extract was obtained from 1.1 kg of dried liberation wind roots according to the method of <Example 1>. 50 g of the extract was suspended in 0.25 L methanol (MeOH), followed by 100% water (100% H 2 O) and different proportions (30%, 60%, 90% and 100%) using Amberlite XAD-4. Methanol extraction of 100% water fraction (100% H 2 O, 42 g), 30% MeOH fraction (30% MeOH, 0.89 g), 60% MeOH fraction (60% MeOH, 1 g) ), 90% MeOH fractions (90% MeOH, 2.3 g) and 100% MeOH fractions (100% MeOH, 1.2 g) were obtained, respectively.
<실시예 3> 세포 독성 실험Example 3 Cytotoxicity Experiment
상기 <실시예 1> 및 <실시예 2>에서 제조한 해방풍 추출물 또는 이의 분획물의 안전성을 확인하기 위하여, MTT 분석에 의해 세포독성을 확인하였다. In order to confirm the safety of the liberation wind extract or fractions thereof prepared in the <Example 1> and <Example 2>, cytotoxicity was confirmed by MTT analysis.
구체적으로, 마우스 대식세포(macrophage) RAW264.7 세포주를 아메리칸 타입 컬쳐 컬렉션(American Type Culture Collection, ATCC, Rockville, MD, USA)으로부터 구입하여 10% 우태아혈청(fetal bovine serum, FBS), 100 units/㎖ 페니실린 및 100 ㎍/㎖ 스트렙토마이신을 첨가한 DMEM 배지로 37℃, 5% CO2 환경하에서 배양하였다. RAW 264.7 대식세포주에 해방풍 추출물 또는 분획물을 농도별로 24시간 동안 배양한 후, 3-(4,5-디메틸티아졸-2-일)-2,5-디페닐테트라졸리움 브로마이드{3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT} 500 ㎍/㎖를 첨가하고 1시간 동안 37℃에서 반응시켰다. 반응 후, 배양액을 모두 제거하고 디메틸설폭사이드(dimethyl sulfoxide, DMSO) 용액을 첨가하여 생성된 포르마잔(formazan)을 용해시킨 뒤, 570 ㎚에서 흡광도를 측정하였다. 측정된 값을 대조군과 비교하여 상대적인 세포생존율(% of control)을 계산하였다. Specifically, mouse macrophage RAW264.7 cell line was purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) to obtain 10% fetal bovine serum (FBS), 100 units. / ㎖ were cultured in the penicillin and 100 ㎍ / ㎖ 37 ℃ in DMEM media supplemented with streptomycin, 5% CO 2 environment. After cultivating the liberation wind extract or fractions in RAW 264.7 macrophage for 24 hours by concentration, 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide {3- (4, 5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide, MTT} 500 μg / ml was added and reacted at 37 ° C. for 1 hour. After the reaction, all of the culture medium was removed and dimethyl sulfoxide (DMSO) solution was added to dissolve the formazan produced. The absorbance was measured at 570 nm. Relative cell viability (% of control) was calculated by comparing the measured value with the control.
그 결과, 도 1에 나타낸 바와 같이, 해방풍 70% 에탄올 추출물, n-헥산 분획물(Hx), 메틸렌클로라이드 분획물(MC), n-부탄올 분획물(BuOH), 100% 물 분획물(100% H2O), 30% 메탄올 분획물(30% MeOH), 60% 메탄올 분획물(60% MeOH) 또는 90% 메탄올 분획물(90% MeOH)은 모든 농도에서 대조군과 비교하여 세포생존율에 유의적인 차이가 없었다. 따라서, 본 발명의 해방풍 추출물 또는 이의 분획물은 세포 독성이 없는 물질임을 확인할 수 있었다(도 1).
As a result, as shown in Figure 1,
<실시예 4> 염증유발 사이토카인(cytokine) 생성 억제 효과Example 4 Inhibitory Effect of Inflammatory Cytokine Production
본 발명의 해방풍 추출물 또는 이의 분획물의 염증 유발 인자에 대한 억제 효과를 알아보기 위하여, 염증유발 사이토카인인 인터루킨-1β(interleukin-1β, IL-1β) 및 종양괴사인자-α(tumor necrosis factor-α, TNF-α)의 생성량을 확인하였다. In order to investigate the inhibitory effect on the inflammatory-inducing factor of the Liberation wind extract or fractions thereof of the present invention, interleukin-1β, which is an inflammatory cytokine, and tumor necrosis factor-α , TNF-α) was confirmed.
구체적으로, RAW264.7 대식세포주에 1 ㎍/㎖의 지질다당류(lipopolysaccharide, LPS)와 해방풍 추출물 또는 분획물을 농도별로 처리하고 20시간 동안 배양한 후, 배지에 분비된 IL-1β 및 TNF-α의 생성량을 ELISA 키트(R&D Systems Inc., Minneapolis, MN, USA)로 분석하였다. 100% 생성량은 LPS만 처리된 군으로 정의하여 해방풍 시료 처리군의 상대적인 생성량(% of control)을 계산하였다. 모든 측정 결과는 평균(mean)과 표준오차(standard deviation, SD)로 나타내었으며, 실험군 간의 차이는 Student's t-test를 사용한 통계학적 분석을 통해 유의성을 판정하였다.Specifically, 1 μg / mL lipopolysaccharide (LPS) and Lipopolysaccharide extract or fractions were treated in RAW264.7 macrophage line by concentration and incubated for 20 hours, followed by the secretion of IL-1β and TNF-α secreted into the medium. Production was analyzed by ELISA kit (R & D Systems Inc., Minneapolis, MN, USA). The 100% production amount was defined as the LPS-treated group to calculate the relative% of control of the liberation wind sample treatment group. All measurements were expressed as mean and standard deviation (SD), and the differences between the groups were determined by statistical analysis using Student's t-test.
그 결과, 도 2에 나타낸 바와 같이, IL-1β의 경우, 해방풍 추출물의 IC50는 881.86 ㎎/㎖로 나타났다. 이와 달리, 해방풍 분획물의 IC50는, n-헥산 분획물(Hx)은 124.45 ㎎/㎖, 메틸렌클로라이드 분획물(MC)은 25.01 ㎎/㎖, n-부탄올 분획물(BuOH)은 170.19 ㎎/㎖, 30% 메탄올 분획물(30% MeOH)은 43.23 ㎎/㎖, 60% 메탄올 분획물(60% MeOH)은 63.16 ㎎/㎖, 90% 메탄올 분획물(90% MeOH)은 29.63 ㎎/㎖로, 추출물에 비해 각각 약 7.1배, 35.3배, 5.2배, 20.5배, 14배 및 29.4배의 현저한 IL-1β 억제 효과를 나타내었다(도 2). As a result, as shown in FIG. 2, in the case of IL-1β, the IC 50 of the liberation extract was 881.86 mg / ml. In contrast, the IC 50 of the liberation fraction was 124.45 mg / ml for the n-hexane fraction (Hx), 25.01 mg / ml for the methylene chloride fraction (MC) and 170.19 mg / ml for the n-butanol fraction (BuOH), 30%. The methanol fraction (30% MeOH) was 43.23 mg / ml, the 60% methanol fraction (60% MeOH) was 63.16 mg / ml, and the 90% methanol fraction (90% MeOH) was 29.63 mg / ml, each about 7.1 compared to the extract. Pear, 35.3 fold, 5.2 fold, 20.5 fold, 14 fold and 29.4 fold showed significant IL-1β inhibitory effects (FIG. 2).
또한, 도 3에 나타낸 바와 같이, TNF-α의 경우, 해방풍 추출물의 IC50는 1146.79 ㎎/㎖로 나타났다. 이와 달리, 해방풍 분획물의 IC50는 n-헥산 분획물(Hx)이 157.84 ㎎/㎖, 메틸렌클로라이드 분획물(MC)은 150.65 ㎎/㎖, n-부탄올 분획물(BuOH)은 68.63 ㎎/㎖, 30% 메탄올 분획물(30% MeOH)은 233.10 ㎎/㎖, 60% 메탄올 분획물(60% MeOH)은 157.54 ㎎/㎖, 90% 메탄올 분획물(90% MeOH)은 45.22 ㎎/㎖로, 추출물에 비해 각각 약 7.3배, 7.6배, 16.6배, 4.9배, 7.3배 및 25.5배의 뛰어난 TNF-α 억제 효과를 나타내었다(도 3). In addition, as shown in FIG. 3, in the case of TNF-α, the IC 50 of the liberation extract was 1146.79 mg / ml. In contrast, the IC 50 of the liberation fraction was 157.84 mg / ml for the n-hexane fraction (Hx), 150.65 mg / ml for the methylene chloride fraction (MC), 68.63 mg / ml for the n-butanol fraction (BuOH) and 30% methanol. The fraction (30% MeOH) was 233.10 mg / ml, the 60% methanol fraction (60% MeOH) was 157.54 mg / ml, and the 90% methanol fraction (90% MeOH) was 45.22 mg / ml, approximately 7.3 times higher than the extract. , 7.6, 16.6, 4.9, 7.3 and 25.5 folds showed excellent TNF-α inhibitory effect (FIG. 3).
따라서, 본 발명의 해방풍 분획물들은 염증성 사이토카인인 IL-1β 및 TNF-α의 생산 및 분비 억제 활성을 가지며, 특히, 분획물의 염증성 사이토카인 억제활성은 추출물에 비해 현저히 뛰어남을 확인하였다.
Therefore, the liberation wind fractions of the present invention have the inhibitory activity of the production and secretion of inflammatory cytokines IL-1β and TNF-α, in particular, it was confirmed that the inflammatory cytokine inhibitory activity of the fraction is significantly superior to the extract.
<제조예 1> 약학적 제제의 제조Preparation Example 1 Preparation of Pharmaceutical Formulation
<1-1> 산제의 제조<1-1> Preparation of powder
본 발명의 실시예 <2-1>의 에틸아세테이트 분획물 2 g2 g of ethyl acetate fraction of Example <2-1> of the present invention
유당 1 gLactose 1 g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
<1-2> 정제의 제조<1-2> Preparation of tablets
본 발명의 실시예 <2-1>의 에틸아세테이트 분획물 100 ㎎100 mg of ethyl acetate fraction of Example <2-1> of the present invention
옥수수전분 100 ㎎
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<1-3> 캡슐제의 제조≪ 1-3 > Preparation of capsules
본 발명의 실시예 <2-1>의 부탄올 분획물 100 ㎎100 mg of butanol fraction of Example <2-1> of the present invention
옥수수전분 100 ㎎
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
<1-4> 환의 제조≪ 1-4 >
본 발명의 실시예 <2-1>의 부탄올 분획물 1 g1 g of butanol fraction of Example <2-1> of the present invention
유당 1.5 gLactose 1.5 g
글리세린 1 g1 g of glycerin
자일리톨 0.5 gXylitol 0.5 g
상기의 성분을 혼합한 후, 통상의 방법에 따라 1 환 당 4 g이 되도록 제조하였다.
After mixing the above components, it was prepared to be 4 g per ring according to a conventional method.
<1-5> 과립의 제조<1-5> Preparation of granules
본발명의 실시예 <2-1>의 부탄올 분획물 150 ㎎150 mg of butanol fraction of Example <2-1> of the present invention
대두 추출물 50 ㎎Soybean extract 50 mg
포도당 200 ㎎200 mg of glucose
전분 600 ㎎600 mg of starch
상기의 성분을 혼합한 후, 30% 에탄올 100 ㎎을 첨가하여 섭씨 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다.
After mixing the above components, 100 mg of 30% ethanol was added and the mixture was dried at 60 캜 to form granules, which were then filled in a capsule.
<제조예 2> 식품의 제조Production Example 2 Preparation of Food
본 발명의 해방풍 추출물의 분획물을 포함하는 식품들을 다음과 같이 제조하였다.
Food containing the fraction of the Libyan wind extract of the present invention was prepared as follows.
<2-1> 밀가루 식품의 제조<2-1> Production of flour food
본 발명의 실시예 <2-1>의 n-헥산 분획물 0.5~5.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하였다.
0.5-5.0 parts by weight of the n-hexane fraction of Example <2-1> of the present invention was added to the flour, and bread, cake, cookies, crackers and noodles were prepared using this mixture.
<2-2> 스프 및 육즙(gravies)의 제조<2-2> Production of soups and gravies
본 발명의 실시예 <2-1>의 n-헥산 분획물 0.1~5.0 중량부를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.
0.1-5.0 parts by weight of the n-hexane fraction of Example <2-1> of the present invention was added to soups and broth to prepare meat products for health promotion, soups of noodles, and broth.
<2-3> 그라운드 비프(ground beef)의 제조<2-3> Preparation of ground beef
본 발명의 실시예 <2-1>의 n-헥산 분획물 10 중량부를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.
10 parts by weight of the n-hexane fraction of Example <2-1> of the present invention was added to the ground beef to prepare a ground beef for health promotion.
<2-4> 유제품(dairy products)의 제조<2-4> Production of Dairy Products
본 발명의 실시예 <2-1>의 n-헥산 분획물 5~10 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
5-10 parts by weight of the n-hexane fraction of Example <2-1> of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
<2-5> 선식의 제조≪ 2-5 >
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
본 발명의 실시예 <2-1>의 에틸아세테이트 분획물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The ethyl acetate fraction of Example <2-1> of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by spraying and drying with a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 실시예 <2-1>의 에틸아세테이트 분획물을 다음의 비율로 배합하여 제조하였다:The grains, seeds and the ethyl acetate fractions of Example <2-1> prepared above were prepared by combining the following ratios:
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
본 발명의 실시예 <2-1>의 에틸아세테이트 분획물(3 중량부),Ethyl acetate fraction of Example <2-1> of the present invention (3 parts by weight),
영지(0.5 중량부), 및(0.5 parts by weight), and
지황(0.5 중량부).
Rhubarb (0.5 parts by weight).
<제조예 3> 음료의 제조Preparation Example 3 Preparation of Beverage
<3-1> 건강음료의 제조<3-1> Preparation of health drink
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 본 발명의 실시예 <2-1>의 에틸아세테이트 분획물 5 g을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 제조하였다.
Substances such as liquid fructose (0.5%), oligosaccharides (2%), sugars (2%), salts (0.5%) and water (75%) and 5 g of ethyl acetate fraction of Example <2-1> of the present invention After homogeneous mixing and sterilization, it was prepared by packaging in a small packaging container such as glass bottles, plastic bottles.
<3-2> 야채 주스의 제조<3-2> Preparation of vegetable juice
본 발명의 실시예 <2-1>의 n-헥산 분획물 5 g을 토마토 또는 당근 주스 1,000 ㎖에 가하여 야채 주스를 제조하였다.
Vegetable juice was prepared by adding 5 g of the n-hexane fraction of Example <2-1> of the present invention to 1,000 ml of tomato or carrot juice.
<3-3> 과일 주스의 제조<3-3> Production of fruit juice
본 발명의 실시예 <2-1>의 n-헥산 분획물 1 g을 사과 또는 포도 주스 1,000 ㎖ 에 가하여 과일 주스를 제조하였다.
1 g of the n-hexane fraction of Example <2-1> of the present invention was added to 1,000 ml of apple or grape juice to prepare a fruit juice.
<제조예 4> 사료첨가제의 제조Preparation Example 4 Preparation of Feed Additives
본 발명자들을 실시예 <2-1>의 부탄올 분획물을 유효성분으로 하여 하기와 같은 조성으로 사료첨가제를 제조하였다.The present inventors prepared the feed additive with the following composition using the butanol fraction of Example <2-1> as an active ingredient.
<사료첨가제의 조성><The composition of the feed additive>
본 발명의 실시예 <2-1>의 부탄올 분획물: 0.1 ~ 20% 중량부,Butanol fraction of Example <2-1> of the present invention: 0.1 to 20% by weight,
지방분해효소(lipase): 0.001 ~ 0.01% 중량부, Lipase: 0.001 to 0.01% by weight,
제 3 인산칼슘: 1 ~ 20% 중량부, Tertiary calcium phosphate: 1-20% by weight,
비타민 E: 0.01 ~ 0.1% 중량부, Vitamin E: 0.01-0.1% by weight,
효소 분말: 1 ~ 10% 중량부, Enzyme powder: 1 to 10% by weight,
유산균: 0.1 ~ 10% 중량부, Lactic acid bacteria: 0.1 to 10% by weight,
바실러스(bacillus) 배양액: 0.01 ~ 10% 중량부, 및Bacillus culture medium: 0.01 to 10% by weight, and
포도당: 20 ~ 90% 중량부.
Glucose: 20 to 90% by weight.
<제조예 5> 화장품의 제조Production Example 5 Preparation of Cosmetics
본 발명의 해방풍 추출물의 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 개선용 화장품을 제조할 수 있다. 본 발명자들은 상기 화장품으로 영양화장수, 크림, 에센스 등의 유화 제형의 화장품 및 유연화장수 등의 가용화 제형의 화장품을 제조하였다.
It is possible to prepare a cosmetic for the prevention and improvement of inflammatory diseases containing a fraction of the liberation wind extract of the present invention as an active ingredient. The present inventors prepared the cosmetic of solubilized formulations such as cosmetics and soft cosmetics of the emulsion formulations such as nutrient cosmetics, creams, essences and the like as the cosmetics.
<5-1> 유화 제형의 화장품 제조<5-1> Cosmetic Preparation of Emulsion Formulation
하기 [표 1]에 기재된 조성으로 유화제형의 화장품을 제조하였다. 제조 방법은 하기와 같다.To the cosmetic composition of the emulsifier type was prepared in the composition shown in Table 1. The manufacturing method is as follows.
1) 1 내지 9의 원료를 혼합한 혼합물을 65 ~ 70℃로 가열하였다.1) The mixture which mixed the raw materials of 1-9 was heated at 65-70 degreeC.
2) 10의 원료를 상기 단계 1)의 혼합물에 투입하였다.2) 10 was added to the mixture of step 1).
3) 11 내지 13의 원료의 혼합물을 65 ~ 70℃로 가열하여 완전히 용해시켰다.3) The mixture of the raw materials of 11-13 was heated to 65-70 degreeC, and was fully dissolved.
4) 상기 단계 3)을 거치면서, 상기 2)의 혼합물을 서서히 첨가하여 8,000 rpm에서 2 ~ 3분간 유화시켰다.4) While passing through the step 3), the mixture of 2) was slowly added to emulsify for 2-3 minutes at 8,000 rpm.
5) 14의 원료를 소량의 물에 용해시킨 후 상기 단계 4)의 혼합물에 첨가하고 2분간 더 유화시켰다.5) The raw material of 14 was dissolved in a small amount of water, and then added to the mixture of step 4) and emulsified for 2 minutes.
6) 15 내지 17의 원료를 각각 평량한 후 상기 단계 5)의 혼합물에 넣고 30초간 더 유화시켰다.6) 15 to 17 of the raw materials were weighed, respectively, and added to the mixture of step 5) and emulsified for 30 seconds.
7) 상기 단계 6)의 혼합물을 유화 후 탈기과정을 거쳐 25 ~ 35℃로 냉각시킴으로써 유화제형의 화장품을 제조하였다.
7) After the emulsification of the mixture of step 6) through a degassing process was cooled to 25 ~ 35 ℃ to prepare an emulsion cosmetic.
모노라우린산 에스테르Polyoxyethylene sorbitan
Monolauric acid ester
<5-2> 가용화 제형의 화장품 제조<5-2> Cosmetic Preparation of Solubilized Formulation
하기 [표 2]에 기재된 조성으로 가용화 제형의 화장품을 제조하였다. 제조 방법은 하기와 같다.A cosmetic of a solubilized formulation was prepared with the composition shown in Table 2 below. The manufacturing method is as follows.
1) 2 내지 6의 원료를 1의 원료(정제수)에 넣고 아직믹서를 이용하여 용해시켰다.1) Raw materials 2 to 6 were placed in raw material 1 (purified water) and dissolved using a still mixer.
2) 8 내지 11의 원료를 7의 원료(알코올)에 넣고 완전용해시켰다.2) The raw materials of 8 to 11 were put into the raw material of 7 (alcohol) and completely dissolved.
3) 상기 단계 2)의 혼합물을 상기 단계 1)의 혼합물에 서서히 첨가하면서 가용화시켰다.
3) The mixture of step 2) was solubilized with slow addition to the mixture of step 1).
하이드로제네이디트에스테르Polyoxyethylene
Hydrogenated Ester
상기와 같이, 본 발명의 해방풍 추출물을 계통 분획하여 제조한 분획물은 염증 억제에 탁월한 효과가 있으므로 염증성 질환의 예방 또는 치료에 관련된 약제, 염증 개선용 기능성 건강식품, 기능성 사료첨가제 또는 화장용 조성물의 개발 및 생산에 유용하게 사용될 수 있다.
As described above, the fractions prepared by systematic fractionation of the liberation wind extract of the present invention has an excellent effect on inhibiting inflammation, the development of drugs related to the prevention or treatment of inflammatory diseases, functional health foods for improving inflammation, functional feed additives or cosmetic compositions And useful for production.
Claims (17)
A composition for the prevention and treatment of inflammatory diseases, comprising methylene chloride fraction obtained by systematic fractionation of Glehnia littoralis extract with n-hexane, methylene chloride, ethyl acetate, n-butanol and water as an active ingredient.
Prevention and treatment of inflammatory disease containing 90% methanol fraction obtained by systematic fractionation of Glehnia littoralis extract into 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol as an active ingredient Composition.
The composition for preventing and treating inflammatory diseases according to claim 1 or 4, wherein the fraction inhibits the production of interleukin-1β (IL-1β).
The method of claim 1 or 4, wherein the fraction is a composition for preventing and treating inflammatory diseases, characterized in that to suppress the production of tumor necrosis factor-α (TNF-α).
The method of claim 1 or 4, wherein the inflammatory disease is dermatitis, allergy, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing Spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute And chronic inflammatory diseases, the composition for the prevention and treatment of inflammatory diseases, characterized in that any one selected from the group consisting of.
Health functional food for the prevention and improvement of inflammatory diseases containing methylene chloride fraction obtained by systematically fractionating liberated wind extract with n-hexane, methylene chloride, ethyl acetate, n-butanol and water as an active ingredient.
Health functional food for the prevention and improvement of inflammatory diseases containing 90% methanol fraction obtained by systematic fractionation of Liberation wind extract into 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol as an active ingredient .
Functional feed additive for the prevention and improvement of inflammatory diseases containing methylene chloride fraction obtained by systematically fractionating liberated wind extract into n-hexane, methylene chloride, ethyl acetate, n-butanol and water as an active ingredient.
Functional feed additive for the prevention and improvement of inflammatory diseases containing 90% methanol fraction obtained by systematic fractionation of Liberation wind extract into 100% water, 30% methanol, 60% methanol, 90% methanol and 100% methanol as an active ingredient .
Cosmetic composition for the prevention and improvement of inflammatory diseases containing a methylene chloride fraction obtained by systematically fractionating the liberation wind extract with n-hexane, methylene chloride, ethyl acetate, n-butanol and water as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100003903A KR101207214B1 (en) | 2010-01-15 | 2010-01-15 | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Glehnia littoralis as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100003903A KR101207214B1 (en) | 2010-01-15 | 2010-01-15 | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Glehnia littoralis as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110083921A KR20110083921A (en) | 2011-07-21 |
KR101207214B1 true KR101207214B1 (en) | 2012-12-12 |
Family
ID=44921381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100003903A KR101207214B1 (en) | 2010-01-15 | 2010-01-15 | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Glehnia littoralis as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101207214B1 (en) |
-
2010
- 2010-01-15 KR KR1020100003903A patent/KR101207214B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20110083921A (en) | 2011-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101115500B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the mixture of extract of Notopterygium incisum and Saposhnikovia divaricata as an effective ingredient | |
KR101382400B1 (en) | Composition comprising Protaetia brevitarsis for preventing and treating Inflammatory Disorder | |
KR100919852B1 (en) | A composition for the prevention and treatment of edema or dermatitis containing Glehnia littoralis Fr. Schmidt et Miquel extract as an active ingredient | |
KR20110136387A (en) | Compositions for prevention and treatment of allergic disease comprising the fractions from the extracts of gardenia jasminoides as an active ingredient | |
KR102182724B1 (en) | Antiinflammatory composition comprising Locusta migratoria extract | |
KR101207239B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Asparagus cochinchinensis as an active ingredient | |
KR102334546B1 (en) | Composition for anti-inflammatory comprising male pupa extract | |
KR20130011111A (en) | Pharmaceutical compositions for preventing or treating inflammatory diseases comprising phytosterol compound | |
KR20130083427A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
KR101487065B1 (en) | A pharmaceutical composition for prevention or treatment of inflammatory disease comprising Myagropsis myagroides extracts or fraction thereof as an effective ingredient | |
KR101069844B1 (en) | A composition for the prevention and treatment of edema or dermatitis containing Angelica decursiva extract or fraction thereof as an active ingredient | |
KR101503352B1 (en) | A composition for skin protection including skin aging, anti-inflammatory comprising the extracts of Lactarius hatsudake as an active ingredients | |
KR20150115414A (en) | The pharmaceutical compositions for prevention or treatment of inflammatory diseases or promotion of wound healing containing ethylacetate fraction of Schizandra chinensis Baillon | |
KR101080927B1 (en) | An anti-inflammatory composition for the prevention and treatment of edema or a variety of inflammations containing Koelreuteria paniculata extract or fraction thereof as an active ingredient | |
KR20150041968A (en) | Composition for the prevention and treatment of inflammatory diseases containing the solvent fractions of Phaeodactylum tricornutum as an active ingredient | |
KR101207214B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Glehnia littoralis as an active ingredient | |
KR101392333B1 (en) | Pharmaceutical compositions comprising extract or fractions of Rhododendron album Blume for prevention and treatment of inflammatory diseases | |
KR101060198B1 (en) | Anti-inflammatory composition for the prevention or treatment of edema or various inflammations containing the Jovan (sub-system) extract or fractions thereof as an active ingredient | |
KR20200089527A (en) | Composition comprising extracts of Acorus gramineus and Dendropanax morbifera for anti-inflammation | |
KR101402599B1 (en) | Composition comprising saussurea pulchella fisch for preventing and treating allergy disease | |
KR102600557B1 (en) | A composition having anti-inflammation activity comprising compounds isolated from the fraction of the Podocarpus macrophyllus extracts as an active ingredient | |
KR101150485B1 (en) | A pharmaceutical composition comprising extract of Alchornea triplinervia for prevention and treatment of asthma or inflammatory diseases | |
KR101031889B1 (en) | A composition commprising Zuonin B or pharmaceutically acceptable salts thereof as an active ingredient for prevention and treatment of inflammatory disease | |
KR101052067B1 (en) | Inflammatory disease prevention or treatment composition containing wild vegetable extract as an active ingredient | |
KR101247706B1 (en) | novel phenylester compound and pharmaceutical compositions for preventing or treating inflammatory diseases comprising the compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |